The company had positioned CagriSema as a more potent successor to its blockbuster obesity shot Wegovy, boosting market expectations that its weight-loss potential was greater than that of U.S. drugmaker Eli Lilly's rival drug Mounjaro. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/novo-nordisk-starts-new-cagrisema-weightloss-drug-trial/121765520